Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 18, 2023

Primary Completion Date

July 17, 2025

Study Completion Date

January 17, 2026

Conditions

Sarcoma

Interventions

DRUG

Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)

VG161:1.0×10\^8PFU/day, intratumoral injection administration for 3 consecutive days, 28 days as a cycle

Trial Locations (1)

RECRUITING

Peking University People's Hospital, Beijing

All Listed Sponsors

lead

CNBG-Virogin Biotech (Shanghai) Ltd.

INDUSTRY